[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-neoplasm-malignant-primary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-neoplasm-malignant-primary":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100539937","trust-ace---anticancer-treatment-cardiotoxicity-identification-by-echocardiography-100539937",false,"NCT06310330","TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","Technology Revising Ultrasound Solutions for Tomorrow - Anticancer-treatment Cardiotoxicity Identification by Echocardiography","TRUST-ACE","Inclusion Criteria:\n\n* Breast cancer and referral for follow-up to identify potential CTRCD\n\nExclusion Criteria:\n\n* Not willing or able to consent","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"NA","TRUST-ACE will compare a simplified echocardiographic protocol focusing on ventricular function with the guideline recommended comprehensive echocardiographic examination using a randomised design in follow-up of breast-cancer patients with respect to identification of cancer treatment related cardiac dysfunction (CTRCD).\n\nSecondly, the study will evaluate whether novel tools used to improve standardization of recordings as well as automated measurements of central measurements, e.g. ejection fraction (EF) and global longitudinal strain (GLS) can improve the precision of echocardiography in daily clinical practice.",[27],"Breast Neoplasm Malignant Primary",[29,30,31,32],"echocardiography","breast cancer","artificial intelligence","cardiotoxicity","RECRUITING","2025-06-05",{"date":36,"type":37},"2025-06-06","ACTUAL",{"date":39,"type":37},"2024-03-08",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"Norwegian University of Science and Technology","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100554937","preoperative-vs-pathologic-size-in-breast-cancer-a-prospective-study-100554937","NCT06505577","Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study","Concordance Between Preoperative Assessments and Pathologic Size Measurements in Breast Cancer: a Prospective Observational Study","Inclusion Criteria:\n\nAdult patients (≥ 19 years old) diagnosed with breast cancer (invasive and in situ).\n\nPatients scheduled for surgical resection of the tumor Availability of both preoperative tumor size assessments and pathologic measurements post-surgery\n\nExclusion Criteria:\n\nPatients with recurrent breast cancer Inflammatory breast cancer Patients who did not undergo surgery Patients whose preoperative tumor size data is not available or deficient for analyzing","19 Years",{"count":55,"type":21},600,"1 Year","OBSERVATIONAL","Breast cancer, the most prevalent malignancy among women globally, is increasing in incidence. While non-metastatic breast cancer requires surgery, determining the optimal extent of resection remains challenging. Inadequate resection margins necessitate reoperation, leading to increased psychological stress, costs, and potentially compromised cosmetic outcomes and prognosis.\n\nAccurate preoperative assessment of resection extent is crucial and involves various factors, including imaging studies, physical examinations, tumor molecular subtypes, and intraductal carcinoma components. This prospective observational study aims to identify and integrate multiple predictive factors to enhance surgical planning and minimize reoperation rates in breast cancer patients.",[60,27],"Mastectomy",[62,60,63],"Breast cancer","Ductal carcinoma in situ","2025-04-03",{"date":66,"type":37},"2025-04-06",{"date":68,"type":37},"2024-08-01",{"date":70,"type":21},"2027-08-30",{"name":72,"class":44},"Incheon St.Mary's Hospital"]